Press release archive 2004

Monday, 27 December 2004
COUNCIL RECOMMENDS APPROVAL OF CRESTOR IN JAPAN AstraZeneca announced today that the Pharmaceuticals Affairs Council has recommended that the Japanese Ministry of Health, Labour and Welfare (MHLW) approve CRESTOR TM (rosuvastatin) in Japan at a dose range of 2.5-20 mg for the treatment of hypercholesterolaemia. The Council’s recommendation is contingent on final agreement of a post marketing surveillance programme. The recommended starting dose of 2.5 mg is in line with normal clinical practice in Japan where, compared to the western world, lower dose
Friday, 17 December 2004
GEFITINIB (IRESSA™) LUNG CANCER ISEL TRIAL SHOWS NO OVERALL SURVIVAL ADVANTAGE IN A HIGHLY REFRACTORY POPULATION AstraZeneca today announced that the initial analysis of the primary endpoint of Study 709, IRESSA Survival Evaluation in Lung cancer (ISEL) with 1692 patients has been conducted, and shows that IRESSA failed to significantly prolong survival in comparison to placebo in the overall population (HR 0.89, p=0.11, Median 5.6 vs 5.1 months), or in patients with adenocarcinoma (HR 0.83, p=0.07, Median 6.3 vs 5.4 months).
Friday, 17 December 2004
CLINICAL AND REGULATORY CHANGES AT ASTRAZENECA AstraZeneca is committed to the development of innovative medicines but Exanta and Iressa, two products based on breakthrough science, have suffered setbacks.
Friday, 17 December 2004
ASTRAZENECA BOARD ANNOUNCEMENT AstraZeneca PLC today confirms the appointment of Louis Schweitzer as non-executive Chairman with effect from 1 January 2005. Percy Barnevik will retire from the Board as Chairman and a Director on 31 December 2004. The appointment of Louis Schweitzer as Chairman was anticipated in the announcement of his appointment as a non-executive Director on 11 March 2004.
Wednesday, 8 December 2004
NEW DATA ESTABLISH ASTRAZENECA’S ARIMIDEX™ (ANASTROZOLE) AS SUPERIOR TO TAMOXIFEN IN PREVENTING CANCER RECURRENCE New data, from the landmark ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial, is presented today at the San Antonio Breast Cancer Symposium, USA.
Monday, 6 December 2004
ASTRAZENECA ANNOUNCES COMPLETION OF ENROLMENT IN SAINT I PHASE III TRIAL OF CEROVIVE® (NXY-059) AstraZeneca announced today that it has ahead of schedule completed the enrolment of patients in SAINT I, one of two Phase III trials (SAINT I and II) being conducted to determine the effect of CEROVIVE (NXY-059) on disability and neurological recovery in acute ischaemic stroke patients.
Wednesday, 1 December 2004
ASTRAZENECA ANNOUNCES TWO BUSINESS MILESTONES FOR SEROQUEL™ AstraZeneca today announces two new business milestones for SEROQUEL (quetiapine), an atypical antipsychotic for the treatment of schizophrenia and acute manic episodes associated with bipolar disorder (manic-depressive illness).
Tuesday, 30 November 2004
ASTRAZENECA STARTS CONSTRUCTION OF $40M MANUFACTURING PLANT IN EGYPT A groundbreaking ceremony today marked the start of construction by AstraZeneca of a $40 million tablet manufacturing plant in Egypt.
Monday, 29 November 2004
EUROPEAN MUTUAL RECOGNITION PROCEDURE APPROVES ASTRAZENECA’S ATACAND® FOR THE TREATMENT OF CHRONIC HEART FAILURE AstraZeneca today announced that the European Mutual Recognition Variation Procedure (MRP) evaluating the use of Atacand® (candesartan cilexetil), a selective angiotensin receptor blocker (ARB) in the treatment of chronic heart failure (CHF) has been completed. Atacand, already a well established antihypertensive therapy, is now indicated for the treatment of patients with heart failure and impaired left ventricle systolic function. The UK was the MRP Reference Member State for marketing approval across a
Monday, 29 November 2004
NEXIUM RECEIVES FDA APPROVAL FOR RISK REDUCTION OF NSAID-ASSOCIATED STOMACH ULCERS AstraZeneca today announced that a new indication for its prescription proton pump inhibitor Nexium® (esomeprazole magnesium) has been approved by the US Food and Drug Administration (FDA). Nexium is now also indicated for reducing the risk of gastric (stomach) ulcers developing among at risk patients on continuous therapy with non-steroidal anti-inflammatory drugs (NSAIDs). The FDA also issued an approvable letter for the indication of the healing of gastric ulcers associated with NSAIDs therapy.